HMCIB SPAC 3 (226340) - Total Liabilities
Based on the latest financial reports, HMCIB SPAC 3 (226340) has total liabilities worth ₩29.73 Billion KRW (≈ $20.15 Million USD) as of September 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See 226340 days of operational coverage to measure how many days the company can operate on defensive assets alone.
HMCIB SPAC 3 - Total Liabilities Trend (2015–2023)
This chart illustrates how HMCIB SPAC 3's total liabilities have evolved over time, based on quarterly financial data. Check 226340 cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
HMCIB SPAC 3 Competitors by Total Liabilities
The table below lists competitors of HMCIB SPAC 3 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
TON Strategy Co
NASDAQ:TONX
|
USA | $5.10 Million |
|
Merafe
JSE:MRF
|
South Africa | ZAC1.10 Billion |
|
Starrag Group Holding AG
SW:STGN
|
Switzerland | CHF231.39 Million |
|
HansBiomed Corporation
KQ:042520
|
Korea | ₩92.52 Billion |
|
ECB Bancorp Inc.
NASDAQ:ECBK
|
USA | $1.49 Billion |
|
Goldshore Resources Inc
V:GSHR
|
Canada | CA$24.55 Million |
|
TMC Life Sciences Bhd
KLSE:0101
|
Malaysia | RM247.86 Million |
|
Davicom Semiconductor Inc
TW:3094
|
Taiwan | NT$104.36 Million |
Liability Composition Analysis (2015–2023)
This chart breaks down HMCIB SPAC 3's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see total assets of HMCIB SPAC 3.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.71 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.54 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.33 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how HMCIB SPAC 3's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for HMCIB SPAC 3 (2015–2023)
The table below shows the annual total liabilities of HMCIB SPAC 3 from 2015 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | ₩47.65 Billion ≈ $32.29 Million |
-19.20% |
| 2022-12-31 | ₩58.97 Billion ≈ $39.96 Million |
-3.55% |
| 2021-12-31 | ₩61.14 Billion ≈ $41.43 Million |
+178.69% |
| 2020-12-31 | ₩21.94 Billion ≈ $14.87 Million |
+208.43% |
| 2019-12-31 | ₩7.11 Billion ≈ $4.82 Million |
-25.38% |
| 2018-12-31 | ₩9.53 Billion ≈ $6.46 Million |
+891.73% |
| 2017-12-31 | ₩961.20 Million ≈ $651.39K |
+3.41% |
| 2016-12-31 | ₩929.50 Million ≈ $629.91K |
+3.73% |
| 2015-12-31 | ₩896.04 Million ≈ $607.24K |
-- |
About HMCIB SPAC 3
Bonne Co., Ltd. develops and supplies cosmetics in South Korea. The company offers skin care products, including whitening, wrinkle and pimple treatment, stem-cell peptide, and nano peptide products; and sun care products comprising fluids, creams, emulsions, etc. It also provides hair and body care products; makeup products, such as foundation, powder, compact, loose powder, BB cream, eye liner,… Read more